The global nucleic acid amplification testing market size was valued at USD 1.78 billion in 2015. Growing demand for advanced diagnostic measures and increasing investments for the development of new biotechnological diagnostic techniques are the key factors propelling the growth of the market. In addition, the growing prevalence of infectious diseases associated with vectors like bacteria & viruses is also fueling the overall growth.
India Nucleic Acid Amplification Testing Market, By Application, 2014 - 2025 (USD Million)
The global prevalence of communicable diseases remains high despite the presence of various diagnostic and therapeutic techniques in the market. The successful management of an infectious disease is highly dependent on accurate identification of the infecting agent. Nucleic acid amplification provides the most precise detection technique for most of the infectious agents. Thus, it is preferred over traditional diagnostic techniques. In addition, favorable initiatives undertaken by the governments worldwide to introduce these tests in various screening programs are expected to impact the sector positively, especially during the former half of the forecast period.
Along with infectious diseases, NAAT is being extensively studied for applications in other fields like cancer, personalized medicine, and forensics. This is expected to spur the demand for NAAT during the forecast period.
Infectious diseases captured the largest share in 2015 owing to the high usage of NAAT for the detection of disease-causing bacteria and viral agents. The growing emphasis on the management of epidemics, including the most recent one of the Zika virus, is expected to maintain the largest share of the segment throughout the forecast period.
The constantly rising burden of mortality of cancer across the world is catching the attention of healthcare agencies. Thus, high demand for effective early diagnostic methods for various cancer types is anticipated to drive the growth of the segment with a significant CAGR during the forecast period.
The target amplification system includes PCR technology, which is widely used because of its operational simplicity and high efficiency. Thus, the segment is expected to dominate the nucleic acid amplification testing market throughout the forecast period with the highest CAGR.
Many of the companies had limited access to the PCR techniques until 2006. Because of the limited access, alternative techniques like signal and probe amplification systems were developed. These techniques have applications in selective cases. These techniques are used in place of PCR to minimize the time and money required for diagnosis in cases such as branched DNA probes and anti-DNA-RNA hybrid antibodies.
Global Nucleic Acid Amplification Testing Market, by Technique, 2015
North America dominated the sector with the largest revenue share in 2015. Factors like the presence of a large number of players, a well-developed healthcare system, high disposable income, and favorable reimbursement policies are contributing to high revenue generation in the region.
The Asia Pacific is expected to show the fastest growth from 2016 to 2025, due to presence of fast-growing economies and favorable demographics, such as the high prevalence of infectious diseases, and rising adoption of the advanced diagnostic technologies. The government initiatives to implement NAT in public health services is anticipated to create growth opportunities in the region.
This market is highly competitive with a few players capturing most of the share. These companies focus more on new product development to maintain their share. Geographical expansion is of strategic importance to maintain competitiveness. The fast-growing biotechnology space in the Asia Pacific is expected to give rise to the number of local players in the region.
Some of the major players operating in this sector include F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Beckman Coulter, Inc.; Abbott Laboratories, Inc.; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; and Bio-Rad Laboratories, Inc.
Report Attribute |
Details |
Market size value in 2020 |
USD 2.80 billion |
Revenue forecast in 2025 |
USD 4.53 billion |
Growth Rate |
CAGR of 10.45% from 2016 to 2025 |
Base year for estimation |
2015 |
Historical data |
2014 - 2015 |
Forecast period |
2016 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2016 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Application, technique, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; India; China; Brazil; Mexico; South Africa |
Key companies profiled |
F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Beckman Coulter, Inc.; Abbott Laboratories, Inc.; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; Bio-Rad Laboratories, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the nucleic acid amplification testing market on the basis of application, techniques, and region:
Application Outlook (Revenue, USD Million, 2014 - 2025)
Infectious Diseases
Virus
Bacteria
Others
Cancer
Personalized Medicine
Genetic and Mitochondrial Disorders
Technique Outlook (Revenue, USD Million 2014 - 2025)
Target amplification systems
Probe amplification systems
Signal amplification
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
China
India
Latin America
Mexico
Brazil
MEA
South Africa
b. The global nucleic acid amplification testing market size was estimated at USD 2.52 billion in 2019 and is expected to reach USD 2.80 billion in 2020.
b. The global nucleic acid amplification testing market is expected to grow at a compound annual growth rate of 10.45% from 2019 to 2025 to reach USD 4.53 billion by 2025.
b. Infectious disease segment dominated the nucleic acid amplification testing market with a share of 69.41% in 2019. This is attributable to high usage of NAAT for detection of disease causing bacteria and viral agents along with growing emphasis on management of epidemics.
b. Some key players operating in the nucleic acid amplification testing market include F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Beckman Coulter, Inc.; Abbott Laboratories, Inc.; Illumina, Inc.; Siemens Healthineers; bioMérieux SA; Novartis AG; and Bio-Rad Laboratories, Inc.
b. Key factors that are driving the market growth include growing demand for the advanced diagnostic measures coupled with increasing investments for development of new biotechnological diagnostic techniques.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.